Catalyst Pharmaceuticals Inc’s filing revealed that its Director Harper Molly unloaded Company’s shares for reported $0.2 million on Dec 15 ’23. In the deal valued at $14.39 per share,14,000 shares were sold. As a result of this transaction, Harper Molly now holds 0 shares worth roughly $0.0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Tierney David S sold 50,000 shares, generating $666,250 in total proceeds. Upon selling the shares at $13.32, the Director now owns 333,541 shares.
Before that, GRANDE ALICIA sold 60,000 shares. Catalyst Pharmaceuticals Inc shares valued at $825,780 were divested by the VP, Treasurer and CFO at a price of $13.76 per share. As a result of the transaction, GRANDE ALICIA now holds 50,557 shares, worth roughly $0.8 million.
Citigroup initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to a Buy in a research note published on March 14, 2024; the price target was $27. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. Oppenheimer began covering CPRX with “an Outperform” recommendation on December 21, 2023. ROTH Capital revised its rating on August 24, 2022. It rated CPRX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of CPRX
On Friday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock fall -5.36% to $15.73. Over the last five days, the stock has lost -2.12%. Catalyst Pharmaceuticals Inc shares have fallen nearly -6.42% since the year began. Nevertheless, the stocks have fallen -2.96% over the past one year. While a 52-week high of $18.22 was reached on 03/01/24, a 52-week low of $11.09 was recorded on 02/08/24. SMA at 50 days reached $14.89, while 200 days put it at $13.87. A total of 0.95 million shares were traded, compared to the trading of 1.87 million shares in the previous session.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 15.43, which if violated will result in even more drops to 15.12. On the upside, there is a resistance level at 16.32. A further resistance level may holdings at 16.90. The Relative Strength Index (RSI) on the 14-day chart is 50.33, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.14, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.84%. Stochastics %K at 39.89% indicates the stock is a holding.
How much short interest is there in Catalyst Pharmaceuticals Inc?
A steep rise in short interest was recorded in Catalyst Pharmaceuticals Inc stocks on Feb 29, 2024, growing by 1.78 million shares to a total of 6.47 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 4.69 million shares. There was a rise of 27.51%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 6.77% of the overall stock float, the days-to-cover ratio (short ratio) rose to 5.01.
The most recent change occurred on September 21, 2018 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating .
